Nelly R Mugo1, Ting Hong2, Connie Celum3, Deborah Donnell4, Elizabeth A Bukusi5, Grace John-Stewart6, Jonathan Wangisi7, Edwin Were8, Renee Heffron2, Lynn T Matthews9, Susan Morrison2, Kenneth Ngure10, Jared M Baeten3. 1. Department of Global Health, University of Washington, Seattle2Centre for Clinical Research Kenya Medical Research Institute, Nairobi, Kenya3Department of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi, Kenya. 2. Department of Global Health, University of Washington, Seattle. 3. Department of Global Health, University of Washington, Seattle4Department of Medicine, University of Washington, Seattle5Department of Epidemiology, University of Washington, Seattle. 4. Department of Global Health, University of Washington, Seattle6Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 5. Department of Global Health, University of Washington, Seattle7Department of Obstetrics and Gynecology, University of Washington, Seattle8Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya. 6. Department of Global Health, University of Washington, Seattle4Department of Medicine, University of Washington, Seattle5Department of Epidemiology, University of Washington, Seattle9Department of Pediatrics, University of Washington, Seattle. 7. The AIDS Support Organization (TASO), Kampala, Uganda. 8. Department of Reproductive Health, Moi University, Eldoret, Kenya. 9. Division of Infectious Disease, Massachusetts General Hospital, Boston13Center for Global Health, Massachusetts General Hospital, Boston. 10. Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Abstract
IMPORTANCE: Antiretroviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of human immunodeficiency virus (HIV) acquisition. PrEP could reduce periconception HIV risk, but the effect on pregnancy outcomes is not well defined. OBJECTIVE: To assess pregnancy incidence and outcomes among women using PrEP during the periconception period. DESIGN, SETTING, AND PARTICIPANTS: Randomized trial among 1785 HIV-serodiscordant heterosexual couples (the Partners PrEP Study) in which the female partner was HIV uninfected that demonstrated that PrEP was efficacious for HIV prevention, conducted between July 2008 and June 2013 at 9 sites in Kenya and Uganda. INTERVENTIONS:Daily oral TDF (n = 598), combination FTC+TDF (n = 566), or placebo (n = 621) through July 2011, when PrEP demonstrated efficacy for HIV prevention. Thereafter, participants continued receiving active PrEP without placebo. Pregnancy testing occurred monthly and study medication was discontinued when pregnancy was detected. MAIN OUTCOMES AND MEASURES: Pregnancy incidence, birth outcomes (live births, pregnancy loss, preterm birth, congenital anomalies), and infant growth. RESULTS: A total of 431 pregnancies occurred. Pregnancy incidence was 10.0 per 100 person-years among women assigned placebo, 11.9 among those assigned TDF (incidence difference, 1.9; 95% CI, -1.1 to 4.9 [P = .22 vs placebo]), and 8.8 among those assigned FTC+TDF (incidence difference, -1.3; 95% CI, -4.1 to 1.5 [P = .39 vs placebo]). Before discontinuation of the placebo treatment group in July 2011, the occurrence of pregnancy loss (96 of 288 pregnancies) was 42.5% for women receiving FTC+TDF compared with 32.3% for those receiving placebo (difference for FTC+TDF vs placebo, 10.2%; 95% CI, -5.3% to 25.7%; P = .16) and was 27.7% for those receiving TDF alone (difference vs placebo, -4.6%; 95% CI, -18.1% to 8.9%; P = .46). After July 2011, the frequency of pregnancy loss (52 of 143 pregnancies) was 37.5% for FTC+TDF and 36.7% for TDF alone (difference, 0.8%; 95% CI, -16.8% to 18.5%; P = .92). Occurrence of preterm birth, congenital anomalies, and growth throughout the first year of life did not differ significantly for infants born to women who received PrEP vs placebo. CONCLUSIONS AND RELEVANCE: Among HIV-serodiscordant heterosexual African couples, differences in pregnancy incidence, birth outcomes, and infant growth were not statistically different for women receiving PrEP with TDF alone or combination FTC+TDF compared with placebo at conception. Given that PrEP was discontinued when pregnancy was detected and that CIs for the birth outcomes were wide, definitive statements about the safety of PrEP in the periconception period cannot be made. These results should be discussed with HIV-uninfected women receiving PrEP who are considering becoming pregnant. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00557245.
RCT Entities:
IMPORTANCE: Antiretroviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of humanimmunodeficiency virus (HIV) acquisition. PrEP could reduce periconceptionHIV risk, but the effect on pregnancy outcomes is not well defined. OBJECTIVE: To assess pregnancy incidence and outcomes among women using PrEP during the periconception period. DESIGN, SETTING, AND PARTICIPANTS: Randomized trial among 1785 HIV-serodiscordant heterosexual couples (the Partners PrEP Study) in which the female partner was HIV uninfected that demonstrated that PrEP was efficacious for HIV prevention, conducted between July 2008 and June 2013 at 9 sites in Kenya and Uganda. INTERVENTIONS: Daily oral TDF (n = 598), combination FTC+TDF (n = 566), or placebo (n = 621) through July 2011, when PrEP demonstrated efficacy for HIV prevention. Thereafter, participants continued receiving active PrEP without placebo. Pregnancy testing occurred monthly and study medication was discontinued when pregnancy was detected. MAIN OUTCOMES AND MEASURES: Pregnancy incidence, birth outcomes (live births, pregnancy loss, preterm birth, congenital anomalies), and infant growth. RESULTS: A total of 431 pregnancies occurred. Pregnancy incidence was 10.0 per 100 person-years among women assigned placebo, 11.9 among those assigned TDF (incidence difference, 1.9; 95% CI, -1.1 to 4.9 [P = .22 vs placebo]), and 8.8 among those assigned FTC+TDF (incidence difference, -1.3; 95% CI, -4.1 to 1.5 [P = .39 vs placebo]). Before discontinuation of the placebo treatment group in July 2011, the occurrence of pregnancy loss (96 of 288 pregnancies) was 42.5% for women receiving FTC+TDF compared with 32.3% for those receiving placebo (difference for FTC+TDF vs placebo, 10.2%; 95% CI, -5.3% to 25.7%; P = .16) and was 27.7% for those receiving TDF alone (difference vs placebo, -4.6%; 95% CI, -18.1% to 8.9%; P = .46). After July 2011, the frequency of pregnancy loss (52 of 143 pregnancies) was 37.5% for FTC+TDF and 36.7% for TDF alone (difference, 0.8%; 95% CI, -16.8% to 18.5%; P = .92). Occurrence of preterm birth, congenital anomalies, and growth throughout the first year of life did not differ significantly for infants born to women who received PrEP vs placebo. CONCLUSIONS AND RELEVANCE: Among HIV-serodiscordant heterosexual African couples, differences in pregnancy incidence, birth outcomes, and infant growth were not statistically different for women receiving PrEP with TDF alone or combination FTC+TDF compared with placebo at conception. Given that PrEP was discontinued when pregnancy was detected and that CIs for the birth outcomes were wide, definitive statements about the safety of PrEP in the periconception period cannot be made. These results should be discussed with HIV-uninfectedwomen receiving PrEP who are considering becoming pregnant. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00557245.
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Nelly R Mugo; Renee Heffron; Deborah Donnell; Anna Wald; Edwin O Were; Helen Rees; Connie Celum; James N Kiarie; Craig R Cohen; Kayitesi Kayintekore; Jared M Baeten Journal: AIDS Date: 2011-09-24 Impact factor: 4.177
Authors: Carla E Ransom; Yanling Huo; Kunjal Patel; Gwendolyn B Scott; Heather D Watts; Paige Williams; George K Siberry; Elizabeth G Livingston Journal: J Acquir Immune Defic Syndr Date: 2013-12-01 Impact factor: 3.731
Authors: A J Wilcox; C R Weinberg; J F O'Connor; D D Baird; J P Schlatterer; R E Canfield; E G Armstrong; B C Nisula Journal: N Engl J Med Date: 1988-07-28 Impact factor: 91.245
Authors: Aderonke Odutola; Kathy Baisley; Richard J Hayes; Mary Rusizoka; Clare Tanton; Helen A Weiss; John Changalucha; David A Ross; Deborah Watson-Jones Journal: Sex Transm Infect Date: 2012-03-21 Impact factor: 3.519
Authors: Peter Cherutich; Reinhard Kaiser; Jennifer Galbraith; John Williamson; Ray W Shiraishi; Carol Ngare; Jonathan Mermin; Elizabeth Marum; Rebecca Bunnell Journal: PLoS One Date: 2012-05-04 Impact factor: 3.240
Authors: Jillian Pintye; Kristin M Beima-Sofie; Grace Kimemia; Kenneth Ngure; Susan Brown Trinidad; Renee A Heffron; Jared M Baeten; Josephine Odoyo; Nelly Mugo; Elizabeth A Bukusi; Maureen C Kelley; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Angela Kaida; Jerome Kabakyenga; Mwebesa Bwana; Francis Bajunirwe; Winnie Muyindike; Kara Bennett; Annet Kembabazi; Jessica E Haberer; Yap Boum; Jeffrey N Martin; Peter W Hunt; David R Bangsberg; Lynn T Matthews Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Ashley A Leech; Dea Biancarelli; Erika Aaron; Emily S Miller; Jenell S Coleman; Peter L Anderson; Hervette Nkwihoreze; Brianne Condron; Meg Sullivan Journal: AIDS Patient Care STDS Date: 2020-07 Impact factor: 5.078